WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital. Additional invest...

• Indigo™ Cotton demonstrated an average yield improvement of 11% in the target environment of West Texas

• Farmers experienced productivity gains in diverse growing conditions without increased use of water or agricultural chemicals

• Novel R&D platform and economic proposition enable continuous...

-Former Biogen leader George Scangos will be CEO, with Vicki Sato as Chairman of the Board
-Company to apply immune programming at unprecedented scale
-Financing led by ARCH Venture Partners, Bill & Melinda Gates Foundation, diverse group of investors

SAN FRANCISCO, Jan. 6, 2017 /PRNewswire-USNewswire/ --...

Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform to Sienna's Growing Pipeline

WESTLAKE VILLAGE, Calif., Dec. 6, 2016 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acqu...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BlackThorn Therapeutics, a clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, announced that it has closed a $40 million Series A financing. The financing was led by founding investor ARCH Ven...

BOSTON, MASS. — July 21, 2016 — Indigo, a company dedicated to harnessing nature to help farmers sustainably feed the planet, announced today that it has closed a $100 million Series C investment, the largest private equity financing in the agriculture technology sector. The round was led by the $54 billi...

STRONG INVESTOR DEMAND INCREASES TOTAL INVESTMENTS TO $46M

Westlake Village, CA, July 12, 2016 – Sienna Biopharmaceuticals, Inc. (Sienna), a clinical stage company focused on medical dermatology and aesthetics, today announced it has completed a second closing of its Series A financing, securing an additio...

Ann Arbor, Michigan-based Millendo Therapeutics (formerly known as Atterocor Inc), a biopharmaceutical company focused on treating orphan and specialty endocrine diseases, has raised $62 million in Series B funding. New Enterprise Associates Inc led the round. Other investors included Roche Venture Fund,...

SAN DIEGO, December 22, 2015 – eFFECTOR Therapeutics, a biopharmaceutical company developing translation regulators for the treatment of cancer, today announced that it has received $40 million in a Series B financing following the advancement of its lead program toward clinical trials. The financing was...